Peter Feldman Highlights Hereditary Factor X Deficiency Day and the Impact of Coagadex Production at Kedrion’s BPL Site
Peter Feldman, Director of Pharmaceuticals and Healthcare at Queen’s House Consulting, shared on LinkedIn:
”On Hereditary Factor X Deficiency Day (10/10), I have been visiting Kedrion’s BPL site in Elstree, UK, meeting some of the one-in-ten-million people* who manufacture Coagadex factor X concentrate for the one-in-one-million people** living with factor X deficiency.
Great to meet friends old and new who maintain supply of this ultra-orphan drug product, purified from human blood plasma (coincidently, it is also International Plasma Awareness Week).
Sorry not to tag you all, but it would exceed my character-count allowance!
In an age where pharma companies are simultaneously celebrated for their innovation and castigated for their commercialism, it important to recognise the needs of people who live life to the max alongside their coagulation factor deficiency and the individual commitment of people across the plasma industry who strive to facilitate this.
*approximately 8 billion people on the planet and approximately 1000 people on the Elstree site = 1 in 10 million (rounded up).”
Read the full factsheet here.
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria